Adiponectin as a Target in Obesity-related Inflammatory State

Author(s): Koji Ohashi, Daisuke Yuasa, Rei Shibata, Toyoaki Murohara, Noriyuki Ouchi

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 15 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


Accumulating evidence indicates that low grade inflammation is closely associated with obesity-related disorders including type 2 diabetes, hypertension and atherosclerosis. Adiponectin is a fat-derived plasma protein with anti-inflammatory functions. Circulating levels of adiponectin are decreased in obese states, and these conditions are broadly associated with various obesity-related diseases. Furthermore, adiponectin has direct protective functions against cardiovascular disease, cerebrovascular disease, non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). In this review, we will focus on the protective functions of adiponectin against these obesity-related diseases from the view point of its anti-inflammatory properties.

Keywords: Adiponectin, cardiovascular disease, cerebrovascular disease, CKD, inflammation, insulin resistance, NASH.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 21 May, 2015
Page: [145 - 150]
Pages: 6
DOI: 10.2174/1871530315666150316122709
Price: $65

Article Metrics

PDF: 40